Top Page
Shanghai Pharmaceuticals Holding Co
(2607)
Shanghai Pharmaceuticals Holding Co (2607) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Pharmaceuticals Holding Co Business Overview & Revenue Model
Shanghai Pharmaceuticals Holding Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 277.43B | 275.25B | 260.30B | 231.98B | 215.82B | 191.91B |
| Gross Profit | 29.40B | 30.63B | 30.93B | 30.49B | 28.54B | 27.44B |
| EBITDA | 11.63B | 12.06B | 10.90B | 12.44B | 10.55B | 10.44B |
| Net Income | 6.07B | 4.55B | 3.77B | 5.62B | 5.09B | 4.50B |
Balance Sheet | ||||||
| Total Assets | 238.07B | 221.21B | 211.97B | 198.13B | 163.44B | 149.19B |
| Cash, Cash Equivalents and Short-Term Investments | 47.50B | 44.38B | 40.67B | 37.01B | 22.39B | 22.30B |
| Total Debt | 51.73B | 47.79B | 42.90B | 38.56B | 31.69B | 31.79B |
| Total Liabilities | 149.21B | 137.47B | 131.65B | 120.13B | 104.37B | 94.44B |
| Stockholders Equity | 75.10B | 71.68B | 68.52B | 67.06B | 49.36B | 45.35B |
Cash Flow | ||||||
| Free Cash Flow | 2.34B | 3.43B | 2.26B | 2.06B | 942.55M | 3.83B |
| Operating Cash Flow | 989.26M | 5.83B | 5.23B | 4.74B | 5.06B | 6.84B |
| Investing Cash Flow | -1.18B | 415.98M | -2.49B | ― | ― | ― |
| Financing Cash Flow | 3.75B | -1.86B | 231.85M | 12.14B | 1.57B | ― |
Shanghai Pharmaceuticals Holding Co Technical Analysis
Shanghai Pharmaceuticals Holding Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $60.53B | 8.24 | 8.74% | 3.70% | -2.68% | -21.45% | |
71 Outperform | $65.17B | 7.24 | 7.53% | 2.65% | 2.77% | 39.24% | |
58 Neutral | HK$9.68B | 51.47 | 5.07% | 1.36% | 0.33% | -44.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shanghai Pharmaceuticals Holding Co Corporate Events
Shanghai Pharmaceuticals Holding Co., Ltd. announced the renewal of its Procurement Framework Agreement with Wing Fat Printing, effective from January 1, 2026, to December 31, 2026. This agreement allows Wing Fat Group to continue supplying printed packaging materials for pharmaceutical products, ensuring the stability of Shanghai Pharmaceuticals’ operations and meeting future demand. The transactions are classified as continuing connected transactions under the Listing Rules, subject to specific reporting and review requirements but exempt from circular and independent shareholders’ approval. The annual cap for these transactions is set at RMB90,000,000, based on estimated future demand and historical procurement amounts. The agreement is expected to benefit the company by reducing administrative costs and maintaining business stability.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has released its third quarterly report for 2025, prepared in accordance with PRC Accounting Standards for Business Enterprises. The report, which has not been audited, emphasizes the company’s commitment to transparency and accuracy in its financial disclosures, as affirmed by its board of directors and senior management. This announcement underscores the company’s adherence to regulatory requirements and its ongoing efforts to maintain trust with stakeholders.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced its proposed 2025 Interim Profit Distribution Plan, which was approved by the board of directors. The company plans to distribute a cash dividend of RMB1.20 per ten shares, amounting to a total of RMB445,003,417.08, representing 9.98% of the consolidated net profit for the first half of 2025. This plan is contingent upon shareholder approval at the upcoming general meeting. The announcement reflects the company’s commitment to returning value to its shareholders and maintaining stable financial operations.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. announced an interim cash dividend of RMB 1.2 per 10 shares for the six months ending June 30, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may influence its market positioning by showcasing financial stability and shareholder confidence.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced a board meeting scheduled for October 30, 2025, to approve the company’s third-quarter results and consider interim dividend payments. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. announced an equity adjustment involving the transfer of the entire equity interest in Shanghai Industrial Investment (Holdings) Company Limited to Golden Bell International Holdings Limited. This adjustment increases the shareholding of Shanghai Shangshi (Group) Co., Ltd. from 25.303% to 38.487% without changing the company’s controlling shareholder or de facto controller, which remains Shanghai SASAC. The adjustment complies with relevant regulations, exempting the acquirer from a mandatory tender offer, and does not trigger any mandatory general offer obligations under Hong Kong’s Code on Takeovers and Mergers.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has released additional information regarding its 2024 annual report, specifically addressing connected transactions and its Share Option Scheme. The company clarified details about ongoing connected transactions with Yunnan Baiyao Group Co., Ltd., Wing Fat Printing Limited, and property leasing agreements with Shanghai Pharma Group. Additionally, the company reported that there were no options available for grant under its Share Option Scheme as of the reporting period, with a total of 680,000 A Shares available for issue, representing a small fraction of the company’s total shares.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. announced a significant change in its shareholder structure, as Shanghai Shangshi Yangtze River Delta Ecological Development Co., Ltd. transferred its 40% equity interest in Shanghai Pharmaceutical (Group) Co., Ltd. to Shanghai Shangshi (Group) Co., Ltd. for RMB6,721.5148 million. This transaction results in Shanghai Shangshi (Group) Co., Ltd. holding 100% of Shanghai Pharmaceutical (Group), which is a controlling shareholder of Shanghai Pharmaceuticals Holding Co., Ltd. The change is expected to have implications for the company’s governance and strategic direction, as well as affecting its market positioning and stakeholder relationships.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. announced a change in shareholder interest following an equity transfer agreement between Shanghai Shangshi (Group) Co., Ltd. and Shanghai International Investment Limited. This transfer, valued at RMB1,484.7498 million, results in Shanghai Industrial Investment (Holdings) Company Limited maintaining control over a significant portion of the company’s shares, totaling 38.465% of the company’s total share capital. This strategic move consolidates SIIC’s control, potentially impacting the company’s market operations and shareholder dynamics.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced the execution of a Share Transfer Agreement to acquire a 10% equity interest in Finance Company from SIIC Dongtan. This strategic acquisition is expected to enhance the company’s financial capabilities and strengthen its market position in the pharmaceutical industry.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., a prominent player in the pharmaceutical industry, is engaged in the research, development, manufacturing, and distribution of pharmaceutical products, with a strong presence in both the industrial and commercial sectors.
Shanghai Pharmaceuticals Holding Co., Ltd. announced its unaudited interim results for the six months ending June 30, 2025. The results, prepared according to Chinese Accounting Standards, have been reviewed by the Board and Audit Committee. The company reported no significant risks affecting its operations during this period, and all directors confirmed the accuracy and completeness of the report.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$14.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced a board meeting scheduled for August 28, 2025, to approve and publish the interim results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$15.70 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.